National Luxembourg Sleep Study: An enriched, at risk, prodromal Parkinson’s Disease cohort
Objective: To identify a cognitively intact enriched cohort of people with isolated rapid eye movement (iREM) sleep behaviour disorder (iRBD) and hyposmia, at risk of…A multimodal approach for diagnosis of early Multiple System Atrophy (MSA)
Objective: To describe the use of neuroimaging and fluid biomarkers to improve the diagnostic accuracy of early MSA. Background: The diagnosis of early MSA is…A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.
Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…Blood derived α-synuclein seeding in the course of Parkinson’s Disease
Objective: To identify seeding capacities of soluble α-synuclein (α-syn) conformers derived from neuronal extracellular vesicles (NEs) from Parkinson´s disease (PD) patients with different disease durations…RT-QuIC for detection of pathological α-synuclein in the olfactory mucosa and CSF of Parkinson’s disease patients
Objective: To investigate the proficiency of RT-QuIC in detecting the presence of misfolded α-synuclein (α-syn) on the olfactory mucosa (OM) and CSF of patients with…Assessment of variation in α-synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia
Objective: To understand molecular heterogeneity among Parkinson’s disease (PD) patients, and controls based on α-synuclein seed amplification assay (SAA) results. Background: α-synuclein seed amplification assay…Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease
Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson’s disorder
Objective: Identification and evaluation of the potential of a novel NLR family pyrin domain containing 3 (NLRP3) inflammasome inhibitor (ZYIL1) as a Parkinson’s disease (PD)…Autosomal dominant Parkinson’s disease caused by SNCA p.E46K variant in family with Russian ancestry: A case report
Objective: To report a family with autosomal dominant Parkinson’s disease (PD) with SNCA p.E46K variant. Background: Alpha-synuclein, encoded by SNCA, is a part of Lewy…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 51
- Next Page »